top of page

How the CDSCO is Transforming Drug Approvals and Safety Standards in India

India's pharmaceutical sector is evolving rapidly, with an increased focus on quality, global compliance, and patient safety. At the heart of this transformation is the Central Drugs Standard Control Organization (CDSCO) — the national regulatory authority for pharmaceuticals and medical devices. As the pharma industry scales new heights in innovation and global outreach, the CDSCO has become a pivotal force in reshaping drug approval timelines, regulatory transparency, and safety protocols.


Drug approval in india

What is the CDSCO?


The CDSCO operates under the Ministry of Health and Family Welfare and is governed by the Drugs and Cosmetics Act, 1940. It is responsible for:

  • Granting drug approvals

  • Regulating clinical trials

  • Monitoring drug safety (pharmacovigilance)

  • Controlling the quality of imported drugs

  • Setting guidelines for the manufacture, distribution, and sale of drugs in India


As India aspires to be a global pharmaceutical leader, the CDSCO’s role in aligning domestic practices with international regulatory standards (USFDA, EMA, MHRA, WHO) has become more critical than ever.


Key Transformations Led by the CDSCO


1. Faster Drug Approval Processes

To boost innovation and access to critical therapies, the CDSCO has:

  • Implemented accelerated approval mechanisms for essential drugs and orphan diseases.

  • Streamlined online approval processes through the SUGAM portal, reducing bureaucratic delays.

  • Enabled parallel submission and fast-track approval for drugs already approved by key international agencies.


2. Strengthening Clinical Trial Regulations

India’s clinical research environment has matured significantly with:

  • Mandatory registration of trials on Clinical Trials Registry – India (CTRI).

  • Strict ethical guidelines and patient consent requirements.

  • Real-time monitoring and transparency in clinical outcomes.


3. Enhanced Pharmacovigilance

The CDSCO’s Pharmacovigilance Programme of India (PvPI) ensures post-marketing surveillance of drugs by:

  • Encouraging healthcare professionals to report adverse drug reactions (ADRs).

  • Collaborating with WHO’s global safety database.

  • Making recall and safety alert mechanisms more responsive.


4. Medical Device Regulation

Previously unregulated, the CDSCO now oversees medical devices under a structured framework, similar to pharmaceuticals. It has introduced:

  • A risk-based classification system

  • Licensing for Class A to D devices

  • Quality assurance through inspections and audits


5. Digital and Transparent Governance

With the adoption of e-Governance, CDSCO has:

  • Made all regulatory approvals, alerts, and licenses accessible online.

  • Improved transparency in decisions and response times.

  • Enabled stakeholders to track application statuses in real time.


Impact on Pharma Companies

These regulatory upgrades have allowed Indian pharmaceutical manufacturers to:

  • Improve compliance readiness for international markets

  • Gain quicker access to domestic and export opportunities

  • Operate in a more predictable and structured regulatory environment

For companies focused on quality, speed, and innovation, the new CDSCO framework is a growth enabler rather than a hurdle.


Are You Seeking a CDSCO-Compliant Manufacturing Partner?

If you’re looking to collaborate with a pharmaceutical manufacturer that aligns with CDSCO and WHO-GMP standards, look no further.


About Suncare Formulations Pvt Ltd


At Suncare Formulations Pvt Ltd, we have over 30 years of experience in pharmaceutical manufacturing. Our WHO-GMP-certified facilities in Dehradun are built to meet both Indian and global regulatory norms.

We specialize in contract manufacturing across 60+ therapies and 400+ formulations, including:

  • Tablets, capsules, syrups, and topicals

  • Government contracts under DRDO and Jan Aushadhi

  • Partnerships with renowned pharma leaders like Lupin, Cadila, and Micro Labs


Leadership & Industry Influence


Our Director, Mr. Sanjay Sikaria, is a key voice in the Indian pharmaceutical ecosystem:

  • Secretary, Drug Manufacturers Association (Dehradun)

  • Secretary, Federation of Pharma Entrepreneurs (FOPE)

  • Director, TIE Dehradun

  • Director, Uni-Scientific Analytical Research Foundation

At Suncare, we don’t just manufacture—we collaborate, comply, and innovate.

Comments

bottom of page